预约演示
更新于：2025-01-23
Hydrochlorothiazide
氢氯噻嗪
更新于：2025-01-23
概要
基本信息
简介氢氯噻嗪是一种小分子药物，作用于噻嗪类敏感氯化钠协同转运蛋白，是噻嗪类敏感氯化钠协同转运蛋白抑制剂。它的适应症包括尿崩症、水肿、高血压和肾结石等。氢氯噻嗪最初由诺华制药公司研发，并于1959年2月12日获得首次批准。该药物通过抑制NCC，减少肾脏中的钠重吸收，从而促进尿液排泄和水分排出，达到利尿的效果。此外，它还可以降低血压和防止肾结石形成。虽然氢氯噻嗪可以缓解症状，但也存在一些不良反应，如低钾血症、头晕、乏力等，需要在医生的指导下使用。总体而言，氢氯噻嗪是一种常用的利尿药和降压药，对多种疾病的治疗具有重要作用。 |
药物类型 小分子化药 |
别名 HCTZ、Hydrochlorothiazide (JP17/USP/INN)、氢氯噻嗪微片 + [10] |
靶点 |
作用机制 NCC抑制剂(噻嗪类敏感氯化钠协同转运蛋白抑制剂) |
最高研发阶段批准上市 |
首次获批日期 美国 (1959-02-12), |
最高研发阶段(中国)批准上市 |
特殊审评- |
登录后查看时间轴
结构/序列
分子式C7H8ClN3O4S2 |
InChIKeyJZUFKLXOESDKRF-UHFFFAOYSA-N |
CAS号58-93-5 |
关联
237
项与 氢氯噻嗪 相关的临床试验CTR20243533
氢氯噻嗪片（25mg）在中国健康受试者中空腹和餐后给药条件下随机、开放、单剂量、两序列、两周期、双交叉生物等效性试验
NCT06111885
Randomized, Double-blind, Crossover Trial Assessing the Efficacy of Indapamide and Chlorthalidone Compared to Hydrochlorothiazide for the Reduction of Urine Supersaturation for Kidney Stone Prevention
ChiCTR2400089563
Clinical study of midapril hydrochloride combined with hydrochlorothiazide in the treatment of essential hypertension
100 项与 氢氯噻嗪 相关的临床结果
登录后查看更多信息
100 项与 氢氯噻嗪 相关的转化医学
登录后查看更多信息
100 项与 氢氯噻嗪 相关的专利（医药）
登录后查看更多信息
7,717
项与 氢氯噻嗪 相关的文献（医药）2025-04-01SPECTROCHIMICA ACTA PART A-MOLECULAR AND BIOMOLECULAR SPECTROSCOPY
Spectrophotometric method based on Continuous wavelet transform and ratio substraction methods for the rapid simultaneous quantification of Valsartan, Amlodipine, and hydrochlorothiazide in cardiovascular tablet formulation
Article
作者: Sohrabi, Mahmoud Reza ; Hajilo, Saeedeh
The present study quantified simultaneous determination of the active components included in Valzomix HCT tablets are hydrochlorothiazide (HCT), valsartan (VAL), and amlodipine (AML). Two chemometric methods-continuous wavelet transform (CWT) and ratio subtraction (RS)-along with a rapid and effective spectrophotometric approach-which does not require preparatory separation-were used to do the analysis. The CWT approach applied the zero-crossing method to analyze several wavelet families and selected the Daubechies 2, Symlet 2, and Biorthogonal 1.3 wavelets. At wavelengths of 215, 224, and 233 nm, respectively, each wavelet was selected based on its unique scale characteristics for the purpose of measuring the medicines. The quantification and detection limits for AML and VAL varied between 0.0406 and 0.3906 μg/mL, with recovery rates sometimes above 97 % and root mean square errors below 2. The RS technique identified satisfactory values between 0.1594 and 0.1663 μg/mL. The recovery rates varied from 99.52 % to 102.70 %, with quantification limits of 0.3064 to 0.7669 μg/mL. Both approaches demonstrated relative standard deviations below 1 % and average recovery rates over 94 % in the sample analysis. A one-way ANOVA with a 95 % confidence interval demonstrated no major variances in the methods.
2025-03-01ENVIRONMENTAL RESEARCH
Pilot-scale adsorption of pharmaceuticals from municipal wastewater effluent using low-cost magnetite-pine bark: Regeneration/enumeration of viable bacteria with a study on their biotoxicity
Article
作者: Risteelä, Sofia ; Mohammadzadeh, Mahdiyeh ; Brandt, Kristian Koefoed ; Lassen, Simon Bo ; Bello, Adedayo ; Leiviskä, Tiina
A low-cost and renewable magnetite-pine bark (MPB) sorbent was evaluated in continuous-flow systems for the removal of various pharmaceuticals from municipal wastewater effluent following membrane bioreactor (MBR) treatment. A 33-day small-scale column test (bed volume: 791 cm3) was conducted using duplicate columns of biochar (BC, Novocarbo) and activated carbon (AC, ColorSorb) as reference for two columns of BC and MPB in order to compare the efficiency of AC and MPB. After the small-scale column test, the pharmaceutical concentrations were generally below the detection limit. In the next stage, a four-month pilot-scale adsorption test was performed using a large column (bed volume: 21 L) filled with BC and MPB. A variety of compounds were removed after the pilot-scale column, including trimethoprim (99.7%), hydrochlorothiazide (81.8%), candesartan (26.0%), carbamazepine (86.1%), ketoprofen (89.4%), clindamycin (86.6%), oxazepam (91.3%), sulfadiazine (38.6%), sulfamethoxazole (58.3%), tramadol (88.9%), zopiclone (73.5%), venlafaxine (93.7%), furosemide (93.5%), fexofenadine (91.6%) and losartan (81.2%). The enumeration of viable bacteria in the pilot-scale column samples revealed that regenerating the BC-MPB bed with NaOH increased bacterial counts in the treated water due to the desorption of adsorbed bacteria from the bed. A biotoxicity study using the Nitrosomonas europaea bioreporter strain indicated that the wastewater was generally non-toxic to this nitrifying bacterium and regeneration of pilot-scale column samples caused short-time toxicity immediately after regeneration. The study confirms that MPB is efficient for the adsorption of pharmaceuticals and can be applied in column mode with a support material such as BC. Therefore, MPB is a viable alternative for AC for the remediation of pharmaceutical-contaminated wastewaters.
2025-03-01EUROPEAN JOURNAL OF PHARMACEUTICAL SCIENCES
3D printed extended-release hydrochlorothiazide tablets
Article
作者: Crcarevska, Maja Simonoska ; Ibrić, Svetlana ; Tasevska, Teodora ; Geskovski, Nikola ; Adamov, Ivana ; Goracinova, Katerina
In this study 3D printed tablets (printlets) with extended release of hydrochlorothiazide (HHT) as model active ingredient were designed and developed. Four formulations, F0.1SSE, F1SSE, F0.1DLP and F1DLP, have been manufactured and characterized, using non-typical semi-solid extrusion (SSE) with UV light solidification and digital light processing (DLP) techniques. Obtained rheological studies pointed out to F1SSE and F1DLP as more suitable for SSE and DLP printing, respectively. Photopolymerization process between photopolymer (PEGDA) and photoinitiator (DPPO; 0.1% and 1%) was investigated using FTIR, with PCA modeling utilized to analyze spectral variations over time and estimate crosslinking kinetics. SSE printlets averaged ∼6.5 mm in diameter, ∼3 mm in height and ∼110 mg in mass, while DLP printlets averaged ∼8.5 mm in diameter, ∼2.5 mm in height, with masses of ∼170 mg (F0.1DLP) and ∼220 mg (F1DLP). All four formulations complied to the requirements of European pharmacopeia for uniformity of dosage units of single dose preparations. In vitro release studies indicated extended-release profiles in both 0.1M Hydrochloric acid (HCl) and phosphate buffer pH 6.8 for SSE and DLP printlets. The release kinetics of HHT from the printlets were modeled to fit First order, Higuchi, Korsmeyer-Peppas and Hixson-Crowell equations and the most probable ones were determined based on the R2 values and Akaike information criterion. FTIR and Raman spectroscopic analyses of printlets confirmed the presence of characteristic peaks from both, HHT and excipients, as well as modifications in bonds due to the photopolymeric reaction.
100 项与 氢氯噻嗪 相关的药物交易
登录后查看更多信息
研发状态
批准上市
10 条最早获批的记录, 后查看更多信息
登录
| 适应症 | 国家/地区 | 公司 | 日期 |
|---|---|---|---|
| 尿崩症 | 中国 | 1981-01-01 | |
| 水肿 | 中国 | 1981-01-01 | |
| 肾石病 | 中国 | 1981-01-01 | |
| 高血压 | 美国 | 1959-02-12 |
未上市
10 条进展最快的记录, 后查看更多信息
登录
| 适应症 | 最高研发状态 | 国家/地区 | 公司 | 日期 |
|---|---|---|---|---|
| 原发性高血压 | 临床3期 | 日本 | 2006-03-01 | |
| 2型糖尿病 | 临床2期 | 加拿大 | 2012-01-01 |
登录后查看更多信息
临床结果
临床结果
适应症
分期
评价
查看全部结果
临床3期 | 13,523 | Chlorthalidone (with prior MI or stroke at baseline) | 簾醖齋膚夢鹽築構蓋淵(鏇鏇襯遞築衊壓齋網齋) = 網構遞繭製顧糧構襯憲 鹹鑰鏇構膚廠簾壓糧願 (觸簾繭獵餘鹽顧艱繭壓 ) 更多 | 积极 | 2024-05-01 | ||
(with prior MI or stroke at baseline) | 簾醖齋膚夢鹽築構蓋淵(鏇鏇襯遞築衊壓齋網齋) = 構鏇齋憲積鬱淵鹽壓構 鹹鑰鏇構膚廠簾壓糧願 (觸簾繭獵餘鹽顧艱繭壓 ) 更多 | ||||||
N/A | 706 | Low thiazide dose | 鏇鏇鏇鹹鹹憲糧鏇衊壓(淵選簾醖衊餘構鏇構簾) = 餘鑰夢鑰遞鏇淵遞鹽壓 憲蓋繭艱選積鏇簾鏇範 (鹽鑰窪遞構鬱糧壓餘糧 ) 更多 | 积极 | 2024-05-01 | ||
Medium thiazide dose | 鏇鏇鏇鹹鹹憲糧鏇衊壓(淵選簾醖衊餘構鏇構簾) = 鑰選願鏇齋齋鏇艱襯鑰 憲蓋繭艱選積鏇簾鏇範 (鹽鑰窪遞構鬱糧壓餘糧 ) 更多 | ||||||
临床3期 | 416 | Placebo oral capsule (Placebo) | 遞糧網網襯憲築選廠餘(積窪遞衊壓製積鏇觸簾) = 壓鑰觸遞膚夢簾顧網廠 構選鏇夢膚鏇鑰衊顧膚 (憲選夢淵壓膚夢餘膚鏇, 窪襯齋壓製鹽齋齋夢糧 ~ 築膚襯鏇淵鬱積範廠鑰) 更多 | - | 2024-02-01 | ||
(12.5 mg Hydrochlorothiazide) | 遞糧網網襯憲築選廠餘(積窪遞衊壓製積鏇觸簾) = 鹽衊積製觸壓網窪餘構 構選鏇夢膚鏇鑰衊顧膚 (憲選夢淵壓膚夢餘膚鏇, 憲積獵糧鬱淵願選醖餘 ~ 餘積艱餘構構廠製鹽鬱) 更多 | ||||||
临床3期 | 230 | Placebo | 選襯夢簾遞鹹鬱顧糧襯(願夢艱窪範廠廠顧壓鬱) = The addition of HCTZ to furosemide was associated to a greatest weight loss at 72/96 h, better metrics of diuretic response and higher 24-h diuresis compared to placebo without significant differences according to sex 觸艱淵觸憲糧觸製鏇築 (窪餘遞繭築製製觸餘鏇 ) 更多 | 积极 | 2024-01-11 | ||
furosemide+hydrochlorothiazide | |||||||
N/A | - | Hydrochlorothiazide (HCT) | 衊顧膚餘壓遞膚鹽鬱餘(積繭顧鏇獵淵餘餘艱簾): IRR = 1.14 (95% CI, 1.06 ~ 1.24) | - | 2023-08-26 | ||
Non-HCT diuretics | |||||||
N/A | 161 | Hydrochlorothiazide 12.5 mg | 積鑰鏇蓋積齋積積觸醖(蓋範顧艱膚蓋廠淵蓋衊): RR = 1.78 (95% CI, 1.12 ~ 1.92), P-Value = 0.023 | - | 2023-05-20 | ||
Loop diuretics | |||||||
N/A | 2,953,748 | 鑰膚顧鑰窪築糧繭齋膚(壓鹽壓構製窪艱願衊鹹): HR = 1.12 (95% CI, 1.03 ~ 1.21), P-Value = ≥10 years | 不佳 | 2023-04-25 | |||
Angiotensin-converting enzyme inhibitors (ACEIs) | |||||||
临床4期 | 49 | (NICHE Method) | 蓋網廠鹽醖衊選製簾範(夢構膚夢鹽獵製鏇構築) = 窪淵膚積餘繭構網鏇積 窪獵獵廠憲廠鹽餘鹹築 (淵簾淵艱膚構簾壓夢襯, 鏇糧襯窪選選構觸鬱選 ~ 鹽鹽鑰鏇範鬱築鑰憲壓) 更多 | - | 2022-09-09 | ||
Usual care (Usual Care) | 蓋網廠鹽醖衊選製簾範(夢構膚夢鹽獵製鏇構築) = 齋繭鬱積廠襯艱網願願 窪獵獵廠憲廠鹽餘鹹築 (淵簾淵艱膚構簾壓夢襯, 鬱襯簾顧廠壓願窪淵積 ~ 夢憲糧獵餘淵窪獵選醖) 更多 | ||||||
N/A | - | 30 | HCTZ 25 mg | 艱簾窪壓鹽鏇繭襯糧願(鑰壓衊選醖衊鹽艱鹽鏇) = 艱壓淵餘窪顧願範選糧 艱醖艱鬱齋窪鬱壓鹽簾 (選壓鹹積構膚遞鹹獵窪 ) | - | 2022-08-28 | |
Placebo | 艱簾窪壓鹽鏇繭襯糧願(鑰壓衊選醖衊鹽艱鹽鏇) = 願網積簾積醖鹽醖襯遞 艱醖艱鬱齋窪鬱壓鹽簾 (選壓鹹積構膚遞鹹獵窪 ) | ||||||
N/A | - | 願衊構夢齋窪築製淵製(願獵廠窪齋鑰觸夢觸鑰) = 廠鏇餘夢糧蓋觸積醖醖 積積選餘壓積範艱夢鹹 (醖淵鑰範廠衊蓋膚糧憲 ) 更多 | - | 2022-06-01 |
登录后查看更多信息
转化医学
使用我们的转化医学数据加速您的研究。
登录
或
药物交易
使用我们的药物交易数据加速您的研究。
登录
或
核心专利
使用我们的核心专利数据促进您的研究。
登录
或
临床分析
紧跟全球注册中心的最新临床试验。
登录
或
批准
利用最新的监管批准信息加速您的研究。
登录
或
特殊审评
只需点击几下即可了解关键药物信息。
登录
或
来和芽仔聊天吧
立即开始免费试用!
智慧芽新药情报库是智慧芽专为生命科学人士构建的基于AI的创新药情报平台，助您全方位提升您的研发与决策效率。
立即开始数据试用!
智慧芽新药库数据也通过智慧芽数据服务平台，以API或者数据包形式对外开放，助您更加充分利用智慧芽新药情报信息。
生物序列数据库
生物药研发创新
免费使用
化学结构数据库
小分子化药研发创新
免费使用